Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab

[1]  R. Vernhout,et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.

[2]  F. Cognetti,et al.  Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas , 2014, BioMed research international.

[3]  R. Touyz,et al.  Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. , 2014, The Canadian journal of cardiology.

[4]  S. Hofer,et al.  Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma – a prospective analysis , 2014, Acta oncologica.

[5]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[6]  R. Soffietti,et al.  What have we learned from trials on antiangiogenic agents in glioblastoma? , 2014, Expert review of neurotherapeutics.

[7]  J. Uhm,et al.  Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial , 2013, Clinical Cancer Research.

[8]  Robert Jeraj,et al.  RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Hoang-Xuan,et al.  Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). , 2013 .

[10]  H. Harputluoglu,et al.  Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO) , 2013, Journal of Cancer Research and Clinical Oncology.

[11]  Juxiang Chen,et al.  The efficacy of temozolomide for recurrent glioblastoma multiforme , 2013, European journal of neurology.

[12]  L. Denaro,et al.  Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature , 2013, Anti-cancer drugs.

[13]  K. Plate,et al.  Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited , 2012, Acta Neuropathologica.

[14]  K. Sugiyama,et al.  Phase II Study of Single-agent Bevacizumab in Japanese Patients with Recurrent Malignant Glioma† , 2012, Japanese journal of clinical oncology.

[15]  S. Hansen,et al.  A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy , 2012, Acta oncologica.

[16]  H. Friedman,et al.  Bevacizumab and daily temozolomide for recurrent glioblastoma , 2012, Cancer.

[17]  R. McLendon,et al.  Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma , 2012, Journal of Neuro-Oncology.

[18]  R. McLendon,et al.  Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy , 2011, Cancer.

[19]  J. Moslehi,et al.  Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. , 2011, Circulation.

[20]  H. Fine,et al.  A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. , 2011, Neuro-oncology.

[21]  R. McLendon,et al.  Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy , 2011, Journal of Neuro-Oncology.

[22]  P. Wen,et al.  Response Assessment in Neuro-Oncology , 2011, Current oncology reports.

[23]  Paul S Mischel,et al.  Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. McLendon,et al.  Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. , 2010, Neuro-oncology.

[25]  M. Bredel,et al.  A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas , 2010, Cancer.

[26]  G. Reifenberger,et al.  Molecular diagnostics of gliomas: state of the art , 2010, Acta Neuropathologica.

[27]  A. Brandes,et al.  Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. , 2010, The oncologist.

[28]  M. Maitland,et al.  Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors , 2010, Journal of the National Cancer Institute.

[29]  S. Hansen,et al.  Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. , 2010, Neuro-oncology.

[30]  W. Mason,et al.  Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  W. Wick,et al.  Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome , 2010, Journal of Neuro-Oncology.

[32]  R. McLendon,et al.  Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study , 2009, British Journal of Cancer.

[33]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  F. Hofstaedter,et al.  MethyQESD, a robust and fast method for quantitative methylation analyses in HNPCC diagnostics using formalin-fixed and paraffin-embedded tissue samples , 2008, Laboratory Investigation.

[36]  E. Perez,et al.  Phase II Study of Gemcitabine Plus Cisplatin in Patients With Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial , 2005, American journal of clinical oncology.

[37]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[38]  G. Gasparini,et al.  Metronomic scheduling: the future of chemotherapy? , 2001, The Lancet. Oncology.

[39]  A. Friedman,et al.  Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. , 2012, International journal of radiation oncology, biology, physics.

[40]  M. Chamberlain,et al.  Salvage therapy with single agent bevacizumab for recurrent glioblastoma , 2009, Journal of Neuro-Oncology.